Aurinia Pharmaceuticals Inc. (AUPH) is a publicly traded company in the Unknown sector. Across all available filings, 22 corporate insiders have executed 156 transactions totaling $50.9M, demonstrating a bearish sentiment with -$21.9M in net insider flow. The most recent transaction on Feb 20, 2026 involved a transaction of 34,638 shares valued at $498.8K.
No significant insider buying has been recorded for AUPH in the recent period.
No significant insider selling has been recorded for AUPH in the recent period.
Based on recent SEC filings, insider sentiment for AUPH is bearish with an Insider Alignment Score of 28/100 and a net flow of -$21.9M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Aurinia Pharmaceuticals Inc. (AUPH) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 22 insiders are actively trading AUPH stock, having executed 156 transactions in the past 90 days. The most active insider is Michael Robert Martin (Executive), who has made 33 transactions totaling $15.3M.
Get notified when executives and directors at AUPH file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | P. Robertson Stephen | EVP, General Counsel | Payment | 34,638 | $14.40 | $498.8K | |
| Feb 2, 2026 | Keenan Greg | SVP, Chief Medical Officer | Payment | 11,552 | $14.53 | $167.9K | |
| Jan 2, 2026 | Greenleaf Peter | Executive | Payment | 113,169 | $15.95 | $1.8M | Large |
| Jan 2, 2026 | Greenleaf Peter | Executive | Award | 165,384 | $N/A | $0 | |
| Nov 21, 2025 | A. Johnson Craig | Executive | Payment | 6,039 | $15.68 | $94.7K | |
| Nov 21, 2025 | Allen Bailey Jeffrey | Executive | Payment | 2,716 | $15.68 | $42.6K | |
| Aug 5, 2025 | Tang Kevin | Executive | Purchase | 200,000 | $11.68 | $2.3M | Large |
| Aug 4, 2025 | Tang Kevin | Executive | Purchase | 100,000 | $11.34 | $1.1M | Large |
| Aug 1, 2025 | Keenan Greg | Executive | Sale | 20,000 | $10.50 | $210.0K | |
| Aug 1, 2025 | Tang Kevin | Executive | Purchase | 1,000,000 | $10.12 | $10.1M | Large |
| Aug 6, 2024 | Michael Habig Scott | Executive | Sale | 18,249 | $5.31 | $96.9K | |
| May 21, 2024 | Hector Mackay-dunn R. | Executive | Sale | 5,630 | $5.74 | $32.3K | |
| May 21, 2024 | Leversage Jill | Executive | Sale | 5,610 | $5.74 | $32.2K | |
| May 21, 2024 | R.w. Jayne David | Executive | Sale | 4,946 | $5.74 | $28.4K | |
| May 21, 2024 | Billen Daniel | Executive | Sale | 5,252 | $5.74 | $30.1K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 69 | $36.4M | 61.7% |
Purchase(P) | 23 | $14.5M | 24.5% |
Exercise(M) | 33 | $5.5M | 9.4% |
Payment(F) | 5 | $2.6M | 4.4% |
Award(A) | 26 | $0 | 0.0% |
Insider selling pressure at Aurinia Pharmaceuticals Inc. has increased, with 22 insiders executing 156 transactions across all time. Total sales of $36.4M significantly outpace purchases of $14.5M, resulting in a net outflow of $21.9M. This selling activity appears largely discretionary, which may warrant closer attention from investors.